#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	12222	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2499	599.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1610	1610	C	749	C	749	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21126	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4136	637.6	0	.	n	.	0	T695C	SNP	695	695	T	1338	1338	C	770	C,T	767,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21126	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4136	637.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1980	1980	A	890	A,T	889,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21126	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4136	637.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2614	2614	C	803	C,T	801,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21126	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4136	637.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2688	2688	A	741	A,T,C	739,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21126	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4136	637.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3240	3240	C	753	C,A,G,T	748,3,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	27	1770	folP	855	855	100.0	folP.l15.c4.ctg.1	2070	106.7	1	SNP	p	R229S	0	.	.	685	687	CGC	1218	1220	CGC	179;182;183	C;G,A;C	179;181,1;183	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4504	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3934	142.8	1	SNP	p	S91F	0	.	.	271	273	TCC	779	781	TCC	141;140;139	T,G;C;C	140,1;140;139	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4504	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3934	142.8	1	SNP	p	D95N	0	.	.	283	285	GAC	791	793	GAC	152;154;152	G;A;C	152;154;152	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4504	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3934	142.8	1	SNP	p	D95G	0	.	.	283	285	GAC	791	793	GAC	152;154;152	G;A;C	152;154;152	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	1662	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1973	105.2	1	SNP	p	G45D	1	.	.	133	135	GAC	758	760	GAC	178;178;178	G;A,G;C	178;177,1;178	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	928	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1695	68.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	4288	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3453	154.8	1	SNP	p	D86N	0	.	.	256	258	GAC	834	836	GAC	190;187;185	G;A;C	190;187;185	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	4288	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3453	154.8	1	SNP	p	S88P	0	.	.	262	264	TCC	840	842	TCC	183;185;187	T;C;C	183;185;187	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3658	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3087	147.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1753	1755	GGC	223;220;219	G;G;C	223;220;219	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2931	140.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1467	1469	GCA	183;183;184	G,A;C;A	182,1;183;184	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2931	140.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1470	1472	ATC	186;183;184	A;T;C	186;183;184	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2931	140.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1482	1484	GTG	186;186;186	G,A;T;G	185,1;186;186	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2931	140.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1482	1484	GTG	186;186;186	G,A;T;G	185,1;186;186	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2931	140.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1986	1988	ACC	185;185;184	A,G;C;C	184,1;185;184	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2931	140.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2040	2042	GCG	209;207;207	G;C,A;G	209;206,1;207	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2931	140.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2040	2042	GCG	209;207;207	G;C,A;G	209;206,1;207	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2931	140.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2163	2165	GGC	168;169;168	G,T;G;C	167,1;169;168	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2931	140.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2172	2174	GGC	175;176;176	G,T;G;C	174,1;176;176	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2931	140.1	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2190	2192	CTG	183;183;183	C;T;G,C	183;183;182,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	4848	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3501	172.5	1	SNP	p	L421P	1	L421P	NONSYN	1261	1263	CTG	1882	1884	CCG	218;220;224	C;C;G	218;220;224	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2082	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2226	116.5	0	.	p	.	0	S22G	NONSYN	64	66	AGC	607	609	GGC	141;142;143	G;G;C	141;142;143	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2082	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2226	116.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	789	789	C	140	C	140	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2564	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2050	155.6	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	872	874	AAG	225;226;225	A;A;G,A	225;226;224,1	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2564	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2050	155.6	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	941	943	CAA	243;244;244	C;A,G;A,G	243;243,1;243,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2564	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2050	155.6	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1148	1150	GAT	219;219;219	G;A;T	219;219;219	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2564	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2050	155.6	0	.	p	.	0	H213G	NONSYN	637	639	CAT	1151	1153	GGT	218;219;220	G,A;G;T	216,2;219;220	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2564	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2050	155.6	0	.	p	.	0	V215D	NONSYN	643	645	GTT	1157	1159	GAT	217;216;211	G,T;A;T,C	216,1;216;210,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2564	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2050	155.6	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1166	1168	ATG	207;208;208	A;T;G	207;208;208	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2564	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2050	155.6	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1283	1285	ACG	201;201;200	A;C,A;G,C	201;200,1;199,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2564	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2050	155.6	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1289	1291	GTT	197;199;196	G;T;T	197;199;196	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2564	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2050	155.6	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1403	1405	AAC	208;210;211	A,G;A;C	207,1;210;211	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2564	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2050	155.6	1	SNP	p	D121N	0	.	.	361	363	GAC	875	877	GAC	226;226;225	G;A,G;C	226;225,1;225	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2564	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2050	155.6	1	SNP	p	A121D	1	.	.	361	363	GAC	875	877	GAC	226;226;225	G;A,G;C	226;225,1;225	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8582	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5272	203.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1268	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1476	107.0	1	SNP	p	V57M	1	.	.	169	171	ATG	760	762	ATG	204;206;206	A,G;T;G	203,1;206;206	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
